Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(CSE:
ACOG
)
0.6500
+0.0500 (+8.33%)
Official Closing Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
67,006
Open
0.6300
Bid (Size)
0.5200 (6,500)
Ask (Size)
0.6900 (8,000)
Prev. Close
0.6000
Today's Range
0.5900 - 0.6500
52wk Range
0.2900 - 0.9900
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
August 19, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
August 13, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Performance
YTD
-7.14%
-7.14%
1 Month
-7.14%
-7.14%
3 Month
-12.16%
-12.16%
6 Month
-2.99%
-2.99%
1 Year
+85.71%
+85.71%
More News
Read More
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
August 12, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
July 29, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
March 08, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
March 05, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Alpha Cognition to Present at the Life Science Investor Forum March 7th
March 01, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
February 22, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Provides Business Update
February 12, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
January 19, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
December 22, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
December 07, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
December 04, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
October 16, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
August 31, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Life Science Investor Forum: Presentations Now Available for Online Viewing
June 23, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
June 20, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Alpha Cognition Launches $6.5 Million Private Placement
May 30, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.